Abstract
Renal Cell Carcinoma (RCC) is the most prominent kidney cancer derived from renal tubules and accounts for roughly 85% of all malignant kidney cancer. Every year, over 60,000 new cases are registered, and about 14,000 people die from RCC. The incidence of this has been increasing significantly in the U.S. and other countries. An increased understanding of molecular biology and the genomics of RCC has uncovered several signaling pathways involved in the progression of this cancer. Significant advances in the treatment of RCC have been reported from agents approved by the Food and Drug Administration (FDA) that target these pathways. These agents have become drugs of choice because they demonstrate clinical benefit and increased survival in patients with metastatic disease. However, the patients eventually relapse and develop resistance to these drugs. To improve outcomes and seek approaches for producing long-term durable remission, the search for more effective therapies and preventative strategies are warranted. Treatment of RCC using natural products is one of these strategies to reduce the incidence. However, recent studies have focused on these chemoprevention agents as anti-cancer therapies given they can inhibit tumor cell grow and lack the severe side effects common to synthetic compounds. This review elaborates on the current understanding of natural products and their mechanisms of action as anti-cancer agents. The present review will provide information for possible use of these products alone or in combination with chemotherapy for the prevention and treatment of RCC.
Highlights
Renal Cell Carcinoma (RCC) is a disease found in the lining of the kidney tubules [1]
We summarize studies on the effects of Epigallocatechin-3-gallate (EGCG), Englerin A, Quercetin, coumarins, curcumin, and other natural products against RCC
This study evaluated the effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), EGCG, and a combination of both on a TRAIL-resistant RCC cell line, 786-O
Summary
Renal Cell Carcinoma (RCC) is a disease found in the lining of the kidney tubules [1]. Significant advances in the treatment of RCC have been derived from agents approved by the FDA that target several pathways. These include inhibitors of mammalian target of rapamycin (mTOR) (e.g., everolimus and temsirolimus) and the tyrosine kinase inhibitors (TKIs) (e.g., sorafenib, sunitinib, pazopanib and axitinib). Sunitinib, pazopanib and axitinib target multiple pro-angiogenic growth factors such as vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF), and their receptors VEGFR and PDGFR These agents were approved by the FDA because they demonstrate clinical activity and increased survival in patients with metastatic disease [11,12,13]. Hchoewmeisvterry, t[h26e]s.eHdorwugesvecra,nthoefsteendrbuegesxctraenmoefltyenexbpeenexsitvreem[2el7y]. exFpuernthsievrem[o2r7e],. tFhuerythuesrmuaolrlye, htahveye iunstuoalellryabhlaevseidinetoelfefercatbslethsaidt emeafkfeecttshethmatpmroahkiebitthiveme toprtorheaibtihtiuvme taontrdeiasteahsuems,ainncdluisdeiansgesh, ainvcinlugdtinhge ohpapvionsgitethoef tohpepionstietnedoefdtheeffeinctte[n23d]e. dInegffeencet r[a2l3, ]h. eIrnbgalenorernaalt,uhrearlbtarel aotrmneanttusrhaal vtreefaetwmetontnsohsaivdee feefwfecttos wnohilseidperoedfufeccitnsg wvehriylefapvroordabulceinregsuvletsryinftauvmoroarbtlreeartemsuelntts [2in3].tuHmoworevtreer,atthmeetnhter[a2p3e].utHicoawcteivveitri,esthoef tthheercaopmeuptoiuc nadctsivwitiitehsinofthtehseecpormodpuocutnsdhsavweitnhoitnbteheensestpurdoideducetxsthenavsievenloytibneRenCCst.uIdt iiesdtheuxstepnrsuidveenlyt tino iRnCvCes.tiIgtaties tthheupsatphrwudaeynstaftfoectinedvebsytigcoamteptohuendpsatihnwthaeysse anfafteucrtaedl pbroyducoctms.pounds in these natural products
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
